Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SIMCERE PHARMA Enters into Exclusive Promotion Service Agreement with PrimeGenX Therapeutics for Pumecitinib Gel
Recommend 3 Positive 4 Negative 0 |
||||
|
||||
|
SIMCERE PHARMA (02096.HK) announced that the Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics in relation to Pumecitinib Gel. Pursuant to the Agreement, the Group will obtain the exclusive promotion rights for Pumecitinib Gel for all dermatology indications in Mainland China, Hong Kong, and Macau. The New Drug Application (NDA) of Pumecitinib Gel for the indication of atopic dermatitis (AD) in adults and adolescents has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This collaboration will further strengthen the Group’s product portfolio in the field of autoimmune diseases. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
